TPC 026
Alternative Names: TPC-026Latest Information Update: 27 Apr 2026
At a glance
- Originator Tetra Pharm Technologies
- Class Hepatoprotectants; Obesity therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Insulin resistance; Non-alcoholic steatohepatitis; Obesity
Most Recent Events
- 03 Feb 2026 Preclinical trials in Insulin resistance in Denmark (unspecified route) prior to February 2026 (Tetra Pharma Technologies pipeline, February 2026)
- 03 Feb 2026 Preclinical trials in Non-alcoholic steatohepatitis in Denmark (unspecified route) prior to February 2026 (Tetra Pharma Technologies pipeline, February 2026)
- 28 Jan 2026 Preclinical trials in Obesity in Denmark (unspecified route) prior to January 2026